Inhaled and Nasal Biologics/DNA Forum 2023
Save the date for a ground-breaking and insightful forum on inhaled and nasal biologics development: Two days of cutting-edge talks and networking opportunities with leaders in this complex area of drug product development.
2nd Annual Inhaled & Nasal Biologics/DNA Forum
28-29th September 2023
With drug discovery programmes increasingly focused on biological drug substances for both local respiratory and systemic targets, the need to develop effective solutions for nasal and inhaled delivery is becoming increasingly important for the industry.
Biologics and DNA modalities present unique challenges for respiratory administration and whilst there can be many ways to design a product, the developer needs to balance, amongst many other things, product performance, manufacturability, regulatory risk, and commercial elements.
With the theme of Building Effective Products, this year's conference features world-renowned industry leaders sharing the latest learnings on inhaled & nasal biologics and DNA medicine development with real-world case studies to stimulate discussion. We'll be focusing on the following topics:
- Choosing The Right Drug Delivery Device
- Designing An Appropriate Formulation
- Overcoming Regulatory Challenges (TBC)
- Learnings from Real World Case Studies
Join industry leading experts for two
days of conference and networking. Save your spot as a key stakeholder in this growing
industry community. Places are limited and so please register your
Wednesday September 27th 2023 - Networking and Optional Lab Tour
- Laboratory Tour (optional) hosted by Intertek laboratory in Melbourn, Cambridgeshire (select option when you register for conference), 2pm
- Optional networking drinks reception, Hinxton Hall, 6pm
Thursday 28th September 2023 - Day 1 of Conference
- Session 1: Real World Case Studies
- Session 2: Overcoming Regulatory Challenges (TBC)
- Panel Discussion
- Networking Drinks 5:30pm
- Evening: Conference Dinner
Friday, 29th September 2023 - Day 2 of Conference
- Session 3: Formulation Strategies
- Session 4: Device Selection
- Conference Close
The registration fee per attendee is shown below. This includes the conference registration, accommodation at Hinxton Hall if required, the conference dinner and networking drinks.
|Rate||Incl. 2 nights' accommodation||Incl. 1 night accommodation||No accommodation required|
|Early Bird Rate (exp. 31 May 2023)||£399||£349||£299|
|Standard Rate (from 1 June 2023)||£449||£399||£349|
Set within a one-hundred-acre estate bordering the River Cam, Hinxton Hall Conference Centre is located on the Wellcome Genome Campus, alongside research institutions that are at the forefront of the genomics revolution.
Hinxton Hall is 25minutes from the centre of Cambridge, and a mere 60 minutes from London and accessible from Heathrow, Luton and Gatwick airports and is only 20minutes from London Stansted Airport. The hall is easily accessible from the M11. For GPS please use: CB10 1SA.
The Intertek team will book accommodation on your behalf if you indicate that you require a room during registration.
QUESTIONS? Please contact us:
T: UK +44 (0)1763 261 648 | E: email@example.com
With drug discovery programmes increasingly focused on biological drug substances for both respiratory and systemic targets, the need to develop effective solutions for nasal and inhaled delivery is becoming increasingly vital for the industry. Biologic and DNA based modalities such as oligonucleotides, proteins, antibodies and a range of other complex forms present unique challenges for developing an effective inhaled and nasal delivery.
With a focus on networking and learning, Intertek was delighted to host the first forum on all aspects of the development of biologic drugs for respiratory delivery which took place at Madingley Hall, Cambridge from 28-30 September 2022.
We thank all of our industry leading experts who joined us for discussions on key principles, challenges, regulatory expectations, best practice and technologies involved in building effective inhaled and nasal DNA or biologic product. The agenda included these talks:
PLENARY: Complex large molecules delivered to the nose and lungs by devices as a combination product. Whatever could be simpler than that!
Eddie J French PhD, TEKH Consulting Limited
Inhaled Biologics – Time to Deliver!
Professor Ben Forbes, Professor of Pharmaceutics, King's College London
Smart nebulizers, the future role of technology in respiratory care
Ulf Krüger, CEO, Pulmotree Medical GmbH
Inhaled IFN-β (SNG001) for the treatment of COVID-19 and other severe viral lung infections
Phillip Monk, Chief Scientific Officer, Synairgen Research Ltd
Inhaled Biologics: What Molecules? What Markets?
Philippe Rogueda – Co-founder and Chief Business Officer, Merxin Ltd.
Fundamentals of OINDP Testing
Mark Parry, Technical Director, Intertek
Fundamentals of DNA Medicines Testing for Inhaled and Nasal Oligonucleotide and mRNA Products
Ashleigh Wake, Intertek Pharmaceutical Services
GMP Pharmaceutical Analysis and Formulation Expertise
Saxon Way, Melbourn
Herts, SG8 6DN
Laboratory Expansion for Specialist OINDP Development for Biologics